ATAI (atai Life Sciences) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Graphic logo of atai.life (ATAI)

Psychedelic development is protected by patents but limited by strict DEA oversight. After evaluating the EV/EBITDA ratio of Atai Life Sciences N.V. (ATAI) in a historical context on GURU.Markets, we find that the latest value is recorded as 0.00. Atai Life Sciences N.V. (ATAI) is accelerating drug creation through M&A deals with laboratories. The brand's high authority in medicine confirms the effectiveness of its platform approach to treating addictions.

ATAI (atai Life Sciences NV) Company Value to EBITDA history from 11/23/2025 to 09/26/2026

Comprehensive metric breakdowns and analytics for atai Life Sciences NV (ATAI)

- market price and analyst price targets:
Initial company analysis:atai ATAI
Product sample of atai Life Sciences

The EV/EBITDA multiple compares the total enterprise value, including net debt, with operating profit before interest, taxes, depreciation, and amortization. By analyzing the EV/EBITDA chart trend for Atai Life Sciences N.V. (ATAI), an investor assesses the capitalization efficiency of the biopharmaceutical ecosystem, where high R&D asset values and synergy among subsidiaries must justify the debt load and ensure platform stability amid shifting market rates.